Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia

被引:24
作者
Longrois, D
de Maistre, E
Bischoff, N
Dopff, C
Meistelman, C
Angioï, M
Lecompte, T
机构
[1] CHU Nancy Brabois, Dept Anesthesia & Intens Care, F-54500 Nancy, France
[2] CHU Nancy Brabois, Dept Hematol, F-54500 Nancy, France
[3] CHU Nancy Brabois, Haemostasis Unit, F-54500 Nancy, France
[4] CHU Nancy Brabois, Dept Cardiovasc Surg, F-54500 Nancy, France
[5] CHU Nancy Brabois, Dept Cardiol, F-54500 Nancy, France
来源
CANADIAN JOURNAL OF ANAESTHESIA-JOURNAL CANADIEN D ANESTHESIE | 2000年 / 47卷 / 03期
关键词
D O I
10.1007/BF03018923
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Purpose: To report the case of a patient with HIT that received a prolonged infusion of r-hirudin (lepirudin; Refludan(R); Hoechst, France) before, during and after cardiopulmonary bypass (CPB) for aortic surgery. Although administration of r-hirudin for CPB anticoagulation has previously been reported, many questions persist concerning the best therapeutic regimen for CPB anticoagulation as well as the time of onset and the doses for post-operative anticoagulation. Clinical Features: A 65-yr-old man was admitted for surgery of aortic stenosis after an episode of acute pulmonary edema complicated by deep venous thrombosis in the context of documented HIT. The patient received r-hirudin for 13 dy before surgery at doses (0.4 mg.kg(-1) bolus followed by 0.15 mg.kg(-1).hr(-1) continuous infusion) that maintained activated partial thromboplastin time (aPTT) ratios between 2 and 2.5. Anticoagulation for CPB was performed with r-hirudin given as 0.1 mg.kg(-1) iv bolus and 0.2 mg.kg(-1) in the CPB priming volume. Anticoagulation during CPB was monitored with the whole blood activated coagulation time and ecarin clotting time (ECT) performed in the operating room with values corresponding to r-hirudin concentrations > 5 mu g.ml(-1) during CPB. Anticoagulation during CPB was uneventful. Two bleeding episodes, related to the r-hirudin regimen and necessitating allogeneic blood transfusion, occurred after surgery. Conclusion: This case report confirms previous experience of the use of r-hirudin for anticoagulation during CPB and provides additional information in the context of prolonged r-hirudin infusion before and after CPB.
引用
收藏
页码:255 / 260
页数:6
相关论文
共 10 条
[1]   Recombinant hirudin in the prevention of venous thromboembolism in patients undergoing elective hip surgery [J].
Agnelli, G ;
Sonaglia, F .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 1997, 23 (02) :143-148
[2]   Hirudin in acute myocardial infarction - Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial [J].
Antman, EM .
CIRCULATION, 1996, 94 (05) :911-921
[3]  
CANNON CP, 1995, J AM COLL CARDIOL, V25, pS30
[4]   Recombinant hirudin (Lepirndin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia -: A prospective study [J].
Greinacher, A ;
Völpel, H ;
Janssens, U ;
Hach-Wunderle, V ;
Kemkes-Matthes, B ;
Eichler, P ;
Mueller-Velten, HG ;
Pötzsch, B .
CIRCULATION, 1999, 99 (01) :73-80
[5]  
NGUYEN P, 1994, NOUV REV FR HEMATOL, V36, P353
[6]  
Nguyen P, 1999, SEMIN THROMB HEMOST, V25, P9
[7]  
Potzsch B, 1997, THROMB HAEMOSTASIS, V77, P920
[8]   RECOMBINANT HIRUDIN AS A NEW ANTICOAGULANT DURING CARDIAC OPERATIONS INSTEAD OF HEPARIN - SUCCESSFUL FOR AORTIC-VALVE REPLACEMENT IN MAN [J].
RIESS, FC ;
LOWER, C ;
SEELIG, C ;
BLEESE, N ;
KORMANN, J ;
MULLERBERGHAUS, G ;
POTZSCH, B .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1995, 110 (01) :265-267
[9]   A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery [J].
Riess, FC ;
Potzsch, B ;
Bader, R ;
Bleese, N ;
Greinacher, A ;
Lower, C ;
Madlener, K ;
MullerBerghaus, G .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1996, 10 (05) :386-388
[10]  
Vanholder R, 1997, THROMB HAEMOSTASIS, V77, P650